Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...
Hosted on MSN14d
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challengesNeurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...
Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Gorman sold ...
Neurocrine Biosciences (NBIX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...
Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...
On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the ...
Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24. Paul Matteis has given his Buy rating due to a combination of factors ...
Hosted on MSN16d
Neurocrine Amends License Agreement with TakedaAn announcement from Neurocrine ( (NBIX)) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive License Agreement with Takeda Pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback